ArticleTranslational lung cancer research2025

Anlotinib enhances the anti-tumor activity of osimertinib in patients with non-small cell lung cancer by reversing drug resistance.

Xin Hua et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.